4//SEC Filing
SUPERNUS PHARMACEUTICALS INC 4
Accession 0001104659-15-024705
$SUPNCIK 0001356576operating
Filed
Mar 30, 8:00 PM ET
Accepted
Mar 31, 4:57 PM ET
Size
9.0 KB
Accession
0001104659-15-024705
Insider Transaction Report
Form 4
Bryan Jones W.
VP of Business Development
Transactions
- Exercise/Conversion
Common Stock
2015-03-30$2.56/sh+6,712$17,183→ 74,692 total - Sale
Common Stock
2015-03-30$12.02/sh−6,712$80,647→ 67,980 total - Exercise/Conversion
Employee Stock Option (Right to Buy)
2015-03-30−6,712→ 30,763 totalExercise: $2.56Exp: 2020-11-02→ Common Stock (6,712 underlying)
Footnotes (3)
- [F1]Transaction made pursuant to a Rule 10b5-1 trading plan adopted on April 21, 2014.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.0000 to $12.1000, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- [F3]The option vested in four equal annual installments beginning on November 2, 2011.
Documents
Issuer
SUPERNUS PHARMACEUTICALS INC
CIK 0001356576
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001356576
Filing Metadata
- Form type
- 4
- Filed
- Mar 30, 8:00 PM ET
- Accepted
- Mar 31, 4:57 PM ET
- Size
- 9.0 KB